# A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

> **NCT05083078** · PHASE1 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 11 (actual)

## Conditions studied

- Arthritis, Psoriatic
- Healthy

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT05083078
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-04
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The study was stopped due to unanticipated feasibility constraints.
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083078, "A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05083078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*